OKYO Pharma (NASDAQ: OKYO) chair boosts stake with 24,551-share buy on Nasdaq

Rhea-AI Filing Summary

OKYO Pharma LTD disclosed that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 of the company’s ordinary shares on Nasdaq on December 15, 2025.

This purchase brings Cerrone’s total holding to 10,516,297 shares of OKYO Pharma. The company has furnished a detailed news announcement about the transaction as Exhibit 99.1 to this report.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

December 2025

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 15, 2025, OKYO Pharma LTD (the “Company”) issued this 6K announcing, that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 24,551 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: December 15, 2025	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated December 15, 2025

4

FAQ

What insider share purchase did OKYO Pharma (OKYO) disclose?

OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 of the company’s ordinary shares on Nasdaq on December 15, 2025.

Who is Panetta Partners Limited in relation to OKYO Pharma (OKYO)?

Panetta Partners Limited is described as an entity in which OKYO Pharma’s Executive Chairman Gabriele Cerrone has a beneficial interest, and it was the purchaser of the 24,551 ordinary shares.

How many OKYO Pharma (OKYO) shares does Executive Chairman Gabriele Cerrone now hold?

Following the reported purchase, Executive Chairman Gabriele Cerrone holds a total of 10,516,297 OKYO Pharma ordinary shares.

On which market were the newly acquired OKYO Pharma (OKYO) shares purchased?

The 24,551 newly acquired OKYO Pharma ordinary shares were purchased on the Nasdaq market.

What exhibit accompanies this OKYO Pharma (OKYO) Form 6-K filing?

The report includes Exhibit 99.1, described as a News Announcement dated December 15, 2025, which provides additional details on the disclosed transaction.

Is the news announcement in Exhibit 99.1 treated as filed with the SEC?

The company states that the information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings except where specifically referenced.